Vir Biotechnology (VIR) Asset Writedowns and Impairment (2020 - 2024)
Vir Biotechnology (VIR) reported Asset Writedowns and Impairment of $11.0 million for Q4 2024, up 300.07% on a YoY basis from $2.8 million in Q1 2024, and up 300.07% sequentially from $2.8 million in Q4 2023.
Vir Biotechnology (VIR) Asset Writedowns and Impairment (2020 - 2024) Analysis & Trends
Vir Biotechnology (VIR) has 3 years of Asset Writedowns and Impairment data on file, last reported at $11.0 million in Q4 2024.
- For the quarter ending Q4 2024, Asset Writedowns and Impairment rose 300.07% year-over-year to $11.0 million; the trailing twelve-month figure through Dec 2025 stood at $11.0 million (down 20.0% YoY), and the FY2024 full-year result was $14.6 million, up 50.65% from the prior year.
- Asset Writedowns and Impairment climbed to $11.0 million in Q4 2024, from $2.8 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $11.0 million in Q4 2024 to a low of $800000.0 in Q3 2020.
- A 3-year average of $4.9 million and a median of $2.8 million in 2023 frame the typical range for Asset Writedowns and Impairment.
- Peak annual rise in Asset Writedowns and Impairment reached 300.07% in 2024, while the deepest fall reached 300.07% in 2024.
- Tracing VIR's Asset Writedowns and Impairment over 3 years: stood at $800000.0 in 2020, then soared by 244.88% to $2.8 million in 2023, then jumped by 300.07% to $11.0 million in 2024.
- Business Quant data shows VIR's Asset Writedowns and Impairment at $11.0 million in Q4 2024, $2.8 million in Q4 2023, and $800000.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - |
| 2 | Nanobiotix | 1,942.19 Bn | 1,942.13 Bn | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - |
| 4 | BeOne Medicines | 475.46 Bn | 470.67 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.19 Bn | 115.94 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.44 Bn | 60.69 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.20 Bn | 63.20 Bn | - |
| 8 | Argenx Se | 57.08 Bn | 51.90 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 38.11 Bn | 38.11 Bn | - |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 11.04 Mn |
| Dec 31, 2024 | 11.04 Mn |
| Dec 31, 2023 | 2.76 Mn |
| Dec 31, 2023 | 2.76 Mn |
| Sep 30, 2020 | 800,000.00 |
| Sep 30, 2020 | 800,000.00 |